Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregor Verhoef

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Blood|April 8, 2009
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO studyLucien Noens, Marie-Anne van Lierde, Robrecht De Bock, et al.
Radiology. Imaging Cancer|April 5, 2021
Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of OutcomeKatja N De Paepe, Ciska-Anne Van Keerberghen, Giorgio M Agazzi, et al.
The Lancet. Oncology|October 24, 2018
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 studyTadeusz Robak, Jie Jin, Halyna Pylypenko, et al.
Plos One|July 25, 2014
Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphomaJulio Finalet Ferreiro, Leila Rouhigharabaei, Helena Urbankova, et al.
Nature Communications|June 18, 2021
Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specifiedKoen Debackere, Lukas Marcelis, Sofie Demeyer, et al.
Leukemia & Lymphoma|February 28, 2013
Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factorsDaan Dierickx, Thomas Tousseyn, Xavier Sagaert, et al.
Leukemia & Lymphoma|June 7, 2017
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>.</sup>Tadeusz Robak, Huiqiang Huang, Jie Jin, et al.
British Journal of Haematology|November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphomaMichelle Fanale, Sarit Assouline, John Kuruvilla, et al.
Haematologica|October 16, 2012
The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorderDaan Dierickx, Thomas Tousseyn, Annelies Requilé, et al.
Leukemia|February 16, 2020
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphomaGeorg Lenz, Eliza Hawkes, Gregor Verhoef, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Blood|April 8, 2009
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO studyLucien Noens, Marie-Anne van Lierde, Robrecht De Bock, et al.
Radiology. Imaging Cancer|April 5, 2021
Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of OutcomeKatja N De Paepe, Ciska-Anne Van Keerberghen, Giorgio M Agazzi, et al.
The Lancet. Oncology|October 24, 2018
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 studyTadeusz Robak, Jie Jin, Halyna Pylypenko, et al.
Plos One|July 25, 2014
Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphomaJulio Finalet Ferreiro, Leila Rouhigharabaei, Helena Urbankova, et al.
Nature Communications|June 18, 2021
Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specifiedKoen Debackere, Lukas Marcelis, Sofie Demeyer, et al.
Leukemia & Lymphoma|February 28, 2013
Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factorsDaan Dierickx, Thomas Tousseyn, Xavier Sagaert, et al.
Leukemia & Lymphoma|June 7, 2017
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<sup>.</sup>Tadeusz Robak, Huiqiang Huang, Jie Jin, et al.
British Journal of Haematology|November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphomaMichelle Fanale, Sarit Assouline, John Kuruvilla, et al.
Haematologica|October 16, 2012
The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorderDaan Dierickx, Thomas Tousseyn, Annelies Requilé, et al.
Leukemia|February 16, 2020
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphomaGeorg Lenz, Eliza Hawkes, Gregor Verhoef, et al.
Pageof 10